Profile data is unavailable for this security.
About the company
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
- Revenue in USD (TTM)0.00
- Net income in USD-140.34m
- Incorporated2013
- Employees112.00
- LocationAllovir Inc1100 Winter StreetWALTHAM 02451United StatesUSA
- Phone+1 (617) 433-2605
- Fax+1 (302) 655-5049
- Websitehttps://www.allovir.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
X4 Pharmaceuticals Inc | 563.00k | 17.63m | 89.47m | 93.00 | 6.20 | 0.9456 | 4.96 | 158.92 | 0.0857 | 0.0857 | 0.0028 | 0.5616 | 0.0029 | -- | 0.6726 | 6,053.76 | 9.18 | -61.53 | 10.59 | -69.20 | 52.40 | -- | 3,131.79 | -13,288.93 | 6.04 | -- | 0.4427 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
CytomX Therapeutics Inc | 119.57m | 11.09m | 89.84m | 120.00 | 8.39 | -- | 6.92 | 0.7513 | 0.1371 | 0.1371 | 1.45 | -0.3997 | 0.6491 | -- | 51.12 | 996,408.30 | 6.02 | -21.53 | 26.34 | -32.32 | -- | -- | 9.27 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
Leap Therapeutics Inc | 0.00 | -60.34m | 90.30m | 54.00 | -- | 1.37 | -- | -- | -2.00 | -2.00 | 0.00 | 1.72 | 0.00 | -- | -- | 0.00 | -67.81 | -80.06 | -80.19 | -95.03 | -- | -- | -- | -7,900.37 | -- | -- | 0.00 | -- | -- | -- | -49.12 | -- | -- | -- |
Genelux Corp | 8.00k | -26.54m | 90.48m | 23.00 | -- | 2.37 | -- | 11,310.37 | -0.9704 | -0.9704 | 0.0003 | 1.11 | 0.0002 | -- | -- | 347.83 | -69.34 | -- | -84.43 | -- | -- | -- | -331,725.00 | -- | -- | -- | 0.00 | -- | -98.46 | -- | -443.44 | -- | -- | -- |
Fibrobiologics Inc | 0.00 | -19.47m | 90.71m | 10.00 | -- | -- | -- | -- | -0.939 | -0.939 | 0.00 | -0.073 | 0.00 | -- | -- | 0.00 | -171.13 | -- | -333.35 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -272.15 | -- | -- | -- |
Ikena Oncology Inc | 1.84m | -66.71m | 93.41m | 18.00 | -- | 0.5776 | -- | 50.66 | -1.43 | -1.43 | 0.0393 | 2.96 | 0.0112 | -- | -- | 42,883.72 | -40.52 | -29.72 | -43.17 | -34.62 | -- | -- | -3,617.57 | -294.90 | -- | -- | 0.00 | -- | -41.35 | 56.05 | 0.8711 | -- | 6.30 | -- |
Allovir Inc | 0.00 | -140.34m | 93.49m | 112.00 | -- | 0.7769 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
MDxHealth SA | 80.74m | -40.80m | 95.05m | 300.00 | -- | -- | -- | 1.18 | -1.54 | -1.54 | 3.06 | -0.3229 | 0.5906 | 9.39 | 7.49 | 269,136.70 | -29.85 | -51.62 | -43.63 | -64.72 | 62.64 | 50.88 | -50.54 | -117.64 | 0.8252 | -1.74 | 1.18 | -- | 89.43 | 19.84 | 2.14 | -- | 30.13 | -- |
Medicinova Inc | 1.00m | -8.16m | 95.64m | 13.00 | -- | 1.67 | -- | 95.64 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
bluebird bio Inc | 54.90m | -311.44m | 95.89m | 375.00 | -- | 1.81 | -- | 1.75 | -2.19 | -2.19 | 0.3574 | 0.2733 | 0.0909 | 3.21 | -- | 146,400.00 | -51.54 | -34.75 | -80.31 | -40.84 | -37.34 | -124.35 | -567.29 | -5,770.41 | 0.5712 | -19.81 | 0.7827 | -- | 720.04 | -11.58 | 8.00 | -- | -30.47 | -- |
Bioatla Inc | 0.00 | -104.56m | 96.67m | 65.00 | -- | 3.08 | -- | -- | -2.18 | -2.18 | 0.00 | 0.6491 | 0.00 | -- | -- | 0.00 | -84.23 | -48.72 | -106.06 | -57.35 | -- | -- | -- | -6,651.71 | -- | -- | 0.00 | -- | -- | -- | -15.95 | -- | -37.01 | -- |
Regulus Therapeutics Inc | 0.00 | -35.39m | 96.89m | 31.00 | -- | 0.9869 | -- | -- | -1.26 | -1.26 | 0.00 | 1.50 | 0.00 | -- | -- | 0.00 | -47.90 | -53.74 | -52.71 | -76.96 | -- | -- | -- | -715.58 | -- | -- | 0.00 | -- | -- | -- | -6.05 | -- | 94.54 | -- |
Oramed Pharmaceuticals, Inc. | 0.00 | 20.86m | 97.85m | 15.00 | 4.80 | 0.5507 | 4.67 | -- | 0.4999 | 0.4999 | 0.00 | 4.36 | 0.00 | -- | -- | 0.00 | 12.19 | -- | 12.29 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -50.43 | -- | 115.11 | -- | -- | -- |
Clearside Biomedical Inc | 7.52m | -33.46m | 97.92m | 30.00 | -- | -- | -- | 13.01 | -0.497 | -0.497 | 0.1119 | -0.3785 | 0.2058 | -- | 59.01 | 250,800.00 | -91.51 | -63.57 | -107.97 | -81.77 | 95.06 | -- | -444.66 | -231.80 | -- | -- | -- | -- | 519.89 | 207.34 | 1.40 | -- | 82.41 | -- |
Tiziana Life Sciences Ltd - ADR | 0.00 | -17.69m | 97.92m | 9.00 | -- | 17.69 | -- | -- | -0.1726 | -0.1726 | 0.00 | 0.0537 | 0.00 | -- | -- | 0.00 | -91.52 | -58.16 | -138.98 | -75.36 | -- | -- | -- | -- | -- | -- | 0.0427 | -- | -- | -- | -14.90 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
EcoR1 Capital, LLCas of 31 Mar 2024 | 11.29m | 9.82% |
Invus Public Equities Advisors LLCas of 25 Jul 2024 | 6.60m | 5.74% |
Octagon Capital Advisors LPas of 31 Mar 2024 | 4.20m | 3.65% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.13m | 2.72% |
Millennium Management LLCas of 31 Mar 2024 | 2.94m | 2.56% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 2.88m | 2.51% |
Irenic Capital Management LPas of 31 Mar 2024 | 2.58m | 2.24% |
Redmile Group LLCas of 31 Mar 2024 | 1.91m | 1.66% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.18m | 1.03% |
Acadian Asset Management LLCas of 30 Jun 2024 | 1.18m | 1.02% |